Sirt2 Deacetylase Is a Novel AKT Binding Partner Critical for AKT Activation by Insulin

• Published in: The Journal of biological chemistry Vol. 289; no. 9; pp. 6054 - 6066
• Main Authors: Ramakrishnan, Gopalakrishnan, Davaakhuu, Gantulga, Kaplun, Ludmila, Chung, Wen-Cheng, Rana, Ajay, Atfi, Azeddine, Miele, Lucio, Tzivion, Guri
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 28.02.2014; American Society for Biochemistry and Molecular Biology
• Subjects: 3T3-L1 Cells; Akt; AMP-activated Kinase (AMPK); Animals; Chlorocebus aethiops; COS Cells; Enzyme Activation - physiology; HeLa Cells; Humans; Insulin; Insulin - genetics; Insulin - metabolism; Mice; NIH 3T3 Cells; Phosphatidylinositol 3-Kinases - genetics; Phosphatidylinositol 3-Kinases - metabolism; Phosphorylation; Phosphorylation - physiology; Protein Binding; Proto-Oncogene Proteins c-akt - genetics; Proto-Oncogene Proteins c-akt - metabolism; Signal Transduction; Sirtuin 1 - antagonists & inhibitors; Sirtuin 1 - genetics; Sirtuin 1 - metabolism; Sirtuin 2 - genetics; Sirtuin 2 - metabolism; Sirtuins; Sirtuins; Phosphorylation; AMP-activated Kinase (AMPK); Akt; Insulin
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M113.537266

AKT/PKB kinases transmit insulin and growth factor signals downstream of phosphatidylinositol 3-kinase (PI3K). AKT activation involves phosphorylation at two residues, Thr308 and Ser473, mediated by PDK1 and the mammalian target of rapamycin complex 2 (mTORC2), respectively. Impaired AKT activation is a key factor in metabolic disorders involving insulin resistance, whereas hyperactivation of AKT is linked to cancer pathogenesis. Here, we identify the cytoplasmic NAD+-dependent deacetylase, Sirt2, as a novel AKT interactor, required for optimal AKT activation. Pharmacological inhibition or genetic down-regulation of Sirt2 diminished AKT activation in insulin and growth factor-responsive cells, whereas Sirt2 overexpression enhanced the activation of AKT and its downstream targets. AKT was prebound with Sirt2 in serum or glucose-deprived cells, and the complex dissociated following insulin treatment. The binding was mediated by the pleckstrin homology and the kinase domains of AKT and was dependent on AMP-activated kinase. This regulation involved a novel AMP-activated kinase-dependent Sirt2 phosphorylation at Thr101. In cells with constitutive PI3K activation, we found that AKT also associated with a nuclear sirtuin, Sirt1; however, inhibition of PI3K resulted in dissociation from Sirt1 and increased association with Sirt2. Sirt1 and Sirt2 inhibitors additively inhibited the constitutive AKT activity in these cells. Our results suggest potential usefulness of Sirt1 and Sirt2 inhibitors in the treatment of cancer cells with up-regulated PI3K activity and of Sirt2 activators in the treatment of insulin-resistant metabolic disorders. AKT kinases mediate insulin signaling downstream of phosphatidylinositol-3 kinase (PI3K). AKT binds Sirt2 in insulin-responsive cells and Sirt2 inhibition blocks AKT activation, whereas Sirt2 overexpression sensitizes cells to insulin. Sirt2 deacetylase is an essential factor in AKT activation. Sirt2 modulators could be useful in treatment of diseases involving AKT, such as type 2 diabetes and cancer.